Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (451-460 of 512) with videos related to

Pageof 52
Sort By:
Oncoimmunology|April 7, 2025
Surrogate markers of intestinal dysfunction associated with survival in advanced cancersRoxanne Birebent, Damien Drubay, Carolina Alves Costa Silva, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2025
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerJessica Menis, Laurent Greiller, Pierre Demontrond, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2019
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul M Putora, Markus Glatzer, José Belderbos, et al.
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 8, 2019
Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]Paul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
Pageof 52

Showing results (451-460 of 512) with videos related to

Sort By:
Pageof 52
Oncoimmunology|April 7, 2025
Surrogate markers of intestinal dysfunction associated with survival in advanced cancersRoxanne Birebent, Damien Drubay, Carolina Alves Costa Silva, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2025
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerJessica Menis, Laurent Greiller, Pierre Demontrond, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2019
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul M Putora, Markus Glatzer, José Belderbos, et al.
NPJ Precision Oncology|December 18, 2021
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancerDiana Schaufler, David F Ast, Hannah L Tumbrink, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 8, 2019
Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]Paul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A Yu, Yasushi Goto, Hidetoshi Hayashi, et al.
Pageof 52